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 28 
Abstract 29 
 30 
Objective: To measure patterns of clinical activity at colposcopy before and after vaccinated women entered 31 
the Scottish Cervical Screening Programme (SCSP). 32 
 33 
Design: Population-based observational study using nationally collected data.  34 
 35 
Setting: Scottish colposcopy clinics. 36 
 37 
Sample: All women with a date of birth on or after 1 January 1985 who attended colposcopy in Scotland 38 
between 2008-2014. 39 
 40 
Methods: Routinely collected data from the Scottish National Colposcopy Clinical Information Audit System 41 
(NCCIAS) was extracted, including: referral criteria, referral cervical cytology, colposcopic findings, clinical 42 
procedures and histology results. Analysis was restricted to those referred to colposcopy at age 20 or 21 years. 43 
 44 
Main outcome measures: Referral criteria, positive predictive value of colposcopy, default rates and rates of 45 
cervical biopsies and treatments. 46 
 47 
Results: 7372 women referred for colposcopy at age 20/ 21 years were identified. There was a downward 48 
trend in the proportion of those referred with abnormal cytology (2008/9: 91.0%, 2013/14: 90.3%, linear trend 49 
p value = 0.03). Women were less likely to have diagnostic or therapeutic interventions. The proportion with 50 
no biopsy (2008/9: 19.5%, 2013/14: 26.9%, linear trend p value < 0.0001) and no treatment (2008/9: 74.9%, 51 
2013/14: 91.8%, linear trend p value < 0.0001) increased over the period of observation.  52 
 53 
Conclusions: A reduction in clinical activity related to abnormal screening referrals is likely to be associated 54 
with the HPV catch-up immunisation programme. Referral criteria and service provision of colposcopy needs 55 
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to be planned carefully taking account of the increasing number of HPV- immunised women that will be 56 
entering cervical screening programmes worldwide. 57 
 58 
Word count 249 59 
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Tweetable Abstract: Colposcopy referral criteria and service planning need attention following HPV 62 
immunisation programme 63 
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 64 
Introduction 65 
Immunisation against the two human papillomavirus (HPV) genotypes,16 and 18 promises a substantial 66 
reduction in high grade cervical intra-epithelial neoplasia (CIN) by 67% and cervical cancers by 70% 1.  These 67 
predictions assume high vaccine uptake and maintenance of existing cervical screening.  Data from Australia2 68 
indicated a significant decrease in high grade cervical cytology in women vaccinated before the age of 18 69 
years.  The realisation of such benefits implies reduced demand for related clinical services. 70 
 71 
In the UK, routine HPV vaccination of girls aged 12-13 in school started in 2008, together with a 3 year  ?ĐĂƚĐŚ-72 
up ? programme for girls up to 18 years designed to expand the immunised cohort and reduce the lag time to 73 
benefit from vaccination 3.  Uptake rates for 3 doses in Scotland are almost 90% of girls routinely immunised in 74 
the school and 65.5% in catch-up4 with equitable uptake by deprivation score5.  75 
 76 
At the time of this study, women became eligible for cervical screening in Scotland at age 20. Women offered 77 
immunisation in the catch up programme therefore became eligible for screening in 2010.. Scottish data from 78 
the catch-up cohort shows reduced prevalence of HPV16/18 in women aged 20 (29.8% to 13.6%)7 and also  of 79 
high risk HPV types, 31, 33 and 45, suggesting cross protection7.  A significant reduction in CIN 1 (RR 0.71), CIN 80 
2 (RR 0.5) and CIN 3 (RR 0.45) was observed in fully vaccinated women compared with unvaccinated women8.  81 
Furthermore, there is a reduction of HPV16/18 in unvaccinated 20 year olds whose peers were vaccinated.7.  82 
While this is encouraging, reduced HPV and CIN prevalence has implications for screening.  We demonstrated 83 
that the predictive values of abnormal cytology for CIN have reduced in immunised women, with a 84 
concomitant significant increase in the referral value (the number of women referred to colposcopy on the 85 
basis of abnormal cytology to detect a case of CIN2+) by 38%9.  86 
 87 
To inform colposcopy service provision as part of a national programme, we measured changes in the referral 88 
and colposcopy activity patterns at a population level using routinely collected data in a cohort of women 89 
offered catch up HPV vaccination.  We aimed to monitor the pattern of new referrals to colposcopy; rates of 90 
interventions; the positive predictive value (PPV) of colposcopic impression for high grade CIN; the negative 91 
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biopsy rate and the rate of default , among young women with increasing rates of HPV vaccination over a 92 
period of observation. 93 
 94 
Methods 95 
We conducted an observational study using national data. Up to 6/6/2016, the eligible population for the 96 
Scottish Cervical Screening programme was women aged 20-60 years with 3 yearly screening using liquid 97 
based cytology. Referral to colposcopy is based on a single high grade result or repeated low grade or 98 
borderline nuclear abnormalities. HPV testing is not used for screening or triage of low grade disease. 99 
Colposcopy data are collected routinely for all women referred to colposcopy in NHS Scotland via the National 100 
Colposcopy Clinical Information and Audit System (NCCIAS),  This is a web-based system which includes 101 
women referred to colposcopy with either abnormal cytology from the screening programme or on clinical 102 
grounds (with no cytology or normal cytology).  Information is episode based and includes patient 103 
demographics, appointment details (including attendance/default), clinical data including indication for 104 
referral (e.g. abnormal cytology, clinical signs and symptoms), colposcopy assessment and findings, biopsy 105 
results, cytology results, treatment methods and the follow-up management plan. Data entry and quality 106 
checks are conducted locally and the data are routinely used to produce clinic correspondence to referring  107 
practitioners and to women, to monitor colposcopy performance for British Society for Colposcopy and 108 
Cervical Pathology (BSCCP) accreditation10 and to bench mark key performance indicators as part of quality 109 
assurance of Scottish colposcopy services.  110 
 111 
We obtained a NCCIAS data extract from NHS Scotland Information and Statistics Division (ISD), which 112 
contained the records for all women whose date of birth was on or after 1 January 1985 and who were 113 
referred to colposcopy in Scotland 2008-2014 inclusive. Data was anonymised by ISD. The analysis was 114 
restricted to those referred for colposcopy at age 20 or 21 to increase the likelihood of women being seen at 115 
colposcopy following their initial cervical screen. The performance of colposcopy was assessed by calculating 116 
the sensitivity, specificity, PPV and negative predictive value (NPV) with the definitive histology result. Women 117 
with normal colposcopy were assumed to have no disease at the time of examination. Performance was 118 
calculated at two different cut-offs of disease outcome: for CIN2+ and for any grade of CIN.  Evidence of a 119 
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linear change in performance indicators and proportions over all time points was assessed by logistic 120 
regression. As a number of models were run, an adjustment for multiple testing, using the Benjamini-Hochberg 121 
false discovery rate procedure was applied, separately to each table, to the traditionally used significance cut-122 
off point of alpha=0.05.  This leads to stricter criteria for declaring statistically significant results and the clinical 123 
significance of all results was also considered. All statistical analysis was conducted in R (R Core Team (2015)), 124 
version 3.1. 125 
 126 
Results 127 
Pattern of referrals  128 
During 2008-2014, there were a total of 31,634 new episodes recorded for women referred to colposcopy with 129 
7372 unique women referred for colposcopy at age 20 or 21 (age 20: 3337, age 21: 4035). The number of 130 
referrals decreased over the period of observation (See Table 1). There was a non-significant downward trend 131 
in the proportion referred with an abnormal screening smear (2008/9; 1294 (91.0%), 2013/14; 758 (90.3%); 132 
linear trend p value = 0.03).  Whilst the absolute numbers declined, the proportion with borderline nuclear 133 
abnormalities (BNA) and low grade dyskaryosis increased with a corresponding reduction in the proportion of 134 
women referred with high-grade dyskaryosis and any grade of dyskaryosis (2008/9; 41.2%, 2013/14; 30.7%; 135 
linear trend p value =0.01).   The number of women with high grade dyskaryosis had more than halved from 136 
533 in 2008/9 to 233 in 2013/14, though the 2008/09 figure is potentially an outlier.   Women are also referred 137 
to colposcopy out with the screening programme for clinical reasons.  For these women, there was an increase 138 
in the proportion referred to colposcopy with a clinically suspicious cervix (2008/9; 1.6%, 2013/14; 3.1%, linear 139 
trend (p = 0.02) but there was no change in the presence of any specific gynaecological symptom (e.g. 140 
intermenstrual bleeding (IMB) or post-coital bleeding (PCB) (See Table 1).  141 
 142 
Rates of diagnostic and therapeutic interventions  143 
Table 2 shows data from 7013 individual women aged 20-21who had a colposcopy examination during 2008-144 
2014. The full data set is available in Table S1.  Women with a colposcopically normal cervix, assessed  by the 145 
absence of abnormal colposcopic features (no acetowhite; no capillary vessel patterns (mosaic and/or 146 
punctation) or no abnormal vessels), increased (2008/9: 138 (10.3%), 2013/14; 112 (14.0%); linear trend p 147 
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value =0.002) while the proportion with a colposcopic impression of high-grade CIN decreased (2008/9; 458 148 
(34.1%), 2013/14; 217 (27.0%); linear trend p value =0.004).  We note that the major change takes place in 149 
2012/13.  Over the period of observation, the proportion of women having no clinical interventions (biopsy or 150 
treatment) increased (2008/9; 19.5%, 2013/14; 26.9%, linear trend p value <0.0001). The proportion having 151 
diagnostic punch biopsy/biopsies or treatment (most commonly loop excision or cold coagulation (also known 152 
as thermocoagulation)) decreased with the number of therapeutic procedures falling from 318 in 2008/9 to 62 153 
in 2013/14. However, we observed an unexpected increase in the proportion of women having a cytology test 154 
performed at colposcopy (2008/9; 4.2%, 2013/14; 5.6%, linear trend p value = 0.02). 155 
 156 
Performance of colposcopy: PPV, sensitivity and specificity for high grade CIN on histology  157 
The number and proportion of women with high grade disease (CIN2+) confirmed on histology decreased 158 
significantly (2008/9; 527 (39.2%), 2013/14; 207 (25.8%), linear trend p value <0.0001). Table 3 shows the 159 
performance of colposcopy to predict or exclude CIN. The PPV of colposcopy for CIN2 or worse (CIN2+) on 160 
biopsy decreased significantly from 79% in 2008/9 to 67% in 2013/14 (linear trend p value =0.0002), though 161 
with the main change associated with 2013/14. The PPV of colposcopy for any grade of CIN or more (CIN+) on 162 
biopsy was relatively unchanged, 84% in 2008/9 and 80% in 2013/14 (linear trend p value = 0.32). We did not 163 
find any significant change in sensitivity and specificity of colposcopy to predict CIN2+ on biopsy over the 164 
period assessed. 165 
 166 
Negative biopsy rate  167 
During 2008-2014, 5535 women aged 20-21 had a biopsy performed at colposcopy visit. The negative biopsy 168 
rate, calculated as the proportion of women who had a biopsy taken but the histology reported as normal or 169 
no CIN, showed no significant change over the period of observation (2008/9; 23.8%, 2009/10; 28.0 %, 170 
2010/11;25.0%, 2011/12; 25.8 %, 2012/13; 25.2% and 2013/14;27.8% linear trend p value = 0.4). 171 
 172 
Default from first attendance at colposcopy rate 173 
The majority of the women (93.9%) attended their first colposcopy appointment within three months from 174 
their date of referral (or date screening cytology reported on SCCRS). Table 4 shows the attendance and 175 
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default rates for colposcopy. The proportion of women who did not attend without prior warning (DNA), 176 
calculated as the proportion of all women given an appointment, decreased significantly over time 177 
(2008/9:26.0%, 2013/14; 17.6%; linear trend p value <0.0001).  178 
 179 
Discussion 180 
Main findings 181 
The results from this ecological population-based study indicate a reduction in the absolute numbers of young 182 
women referred to colposcopy from the catch-up cohort offered HPV immunisation. The timeframe of the 183 
data collection and the size of the effect suggests that this is likely to be associated with HPV vaccination. 184 
Previous studies have confirmed the reduction in HPV vaccine type genotypes and performance of cytology as 185 
a consequence of immunisation 5-9 flagging up the need to review the screening pathway.  This is the first 186 
population-based study to demonstrate reduced colposcopy activity and performance. We have also 187 
confirmed the reported changes in colposcopy performance linked to vaccine status11.  The majority of HPV 188 
vaccine impact studies have focused on the effect on circulating HPV types 6,7, 12, 13 and screening cytology 2, 189 
8,9,12.  The sentinel surveillance system in the United States reported a 26% reduction in HPV16/18 associated 190 
CIN2+ following HPV vaccination14  but did not discuss the impact on service provision..   191 
 192 
Clearly, in countries with both vaccination and cervical screening, the screening programme criteria for referral 193 
to colposcopy must be reviewed to ensure effective delivery of colposcopy services and to minimise the 194 
disbenefits of over-diagnosis in low risk women. Employing such a risk-stratified approach may further reduce 195 
the colposcopy work load with implications for service delivery including recruitment and retention of staff, 196 
maintaining quality and performance, and ensuring equitable access for women.  197 
 198 
Although the numbers are small, the proportion of women referred to colposcopy with gynaecological signs, 199 
has increased.  . 'ǇŶĂĞĐŽůŽŐǇƐĞƌǀŝĐĞƐĂůůŽĐĂƚĞƉĂƚŝĞŶƚƐǁŝƚŚ ?ƌĞĚĨůĂŐ ?ƐǇŵƉƚŽŵƐŽĨĐĞƌǀŝĐĂůĐĂŶĐĞƌƚŽĚŝĨĨĞƌĞŶƚ200 
services which may include colposcopy, general gynaecology, gynaecology/oncology or sexual health. The 201 
increase in symptomatic women may be the result of optimising spare colposcopy clinic capacity by accepting 202 
referrals which could otherwise be seen at other clinics, rather than being driven by increased suspicion of 203 
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cervical cancer in this low risk cohort.  This would maintain skills and the use of colposcopy clinic capacity, time 204 
and staffing, relieving pressure on other gynaecology services. 205 
 206 
The increase in cytology sampling at colposcopy could have two explanations: either a relative increase in the 207 
number of women with symptoms who are due for screening; or colposcopists managing their own clinical 208 
uncertainty by repeating cytology.  The latter is not evidence-based and should be addressed at clinic and 209 
national guideline level to avoid unnecessary procedures which are unlikely to contribute effectively to patient 210 
management 211 
 212 
 213 
Importantly, we are reporting on women who meet the criteria for colposcopy referral (which include 214 
persistent low grade disease) compared with single abnormalities reported in the screened population8.  215 
Before vaccination, the risk of associated CIN with persistent low grade changes was sufficient to warrant 216 
investigation at colposcopy.  In our analysis, we identified an increase in women referred with no identifiable 217 
CIN  This corroborates our previous observation that the referral value of cytology increased in immunised 218 
women9 strengthening the need to review referral criteria to reflect the reduced risk of underlying CIN.  219 
National direction from the screening programme may be necessary to address the issues of referral criteria, 220 
capacity and clinical management highlighted by our results. 221 
 222 
Strengths and limitations 223 
Our study uses nationwide colposcopy data on all women referred to colposcopy in NHS Scotland- the 224 
organised nature of the screening programme advocates that national guidelines are followed, mitigating to an 225 
extent the influence of individualised practice.  Lead colposcopists are responsible for data entry and quality 226 
management of data within NCCIAS15.   227 
 228 
This is an ecological study but although there is no linkage from NCCIAS to the national immunisation record, 229 
the magnitude of the change in activity at colposcopy, the temporal relationship with implementation of 230 
immunisation and the effect reported from screening data in Scotland 7,8, 9  indicates that these effects are 231 
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attributable to HPV immunisation.  Although completion of 3 doses has been reported at over 65% in the 232 
catch-up cohort, this was highest in those girls vaccinated in school (80% uptake) and lower (30% uptake) in 233 
those who had left school5.  Our data comes from the catch-up programme and the maximum effect, when 234 
women vaccinated in the school programme attend screening, is yet to be seen.  235 
 236 
 Our results could be affected by a number of possible biases. Following the death of a media celebrity in the 237 
UK in 2009, there was an increase in the uptake of screening and detection of CIN and cervical cancer 238 
particularly in younger women which was not subsequently sustained 17.  This would account for the number 239 
of abnormalities detected in 2009 compared with previous or subsequent years. There was national 240 
standardisation of referral criteria for low grade dyskaryosis from a single to two consecutive low-grade 241 
cytology tests in 2012, bringing two of the larger health boards into alignment with the practice of the 242 
remaining 12 Scottish boards. In 2013, cytology terminology changed so  ?BNA with koilocytes ? were classified 243 
as low grade dyskaryosis.  This will have altered the reporting profile but would not explain the increase in BNA 244 
reports.  We have previously reported that the number of young women participating in screening has not 245 
decreased in recent years so fewer cases does not reflect lower attendance9. The HPV vaccination campaign 246 
prompted dissemination of information on HPV and immunisation for girls and parents including in the 247 
national media.  The effect of these factors cannot be measured in this study. 248 
 249 
Interpretation 250 
 251 
The demand for colposcopy services is influenced by a number of factors including the target screening 252 
population, the screening test used, and the referral criteria. Other influences include vaccine uptake rates, 253 
the type of vaccine and the dosing schedule as well the health-seeking behaviours of the population.  254 
Colposcopy requirements of the screening programme will fall and spare capacity at colposcopy carries a cost 255 
to the health service. Using colposcopy services to manage gynaecological conditions may not be the most 256 
efficient use of a specialist resource but may allow colposcopists to see sufficient numbers of women to 257 
maintain their pattern recognition and operative skills, and assure quality of the service 10. In the UK, the key 258 
performance indicator is the positive predictive value (PPV) of colposcopy with the lowest acceptable PPV of 259 
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colposcopy for high grade CIN set at 65% 18. Our data indicates that the PPV of colposcopy in women aged 20-260 
21 years is now just above this bench mark indicating that the cut-off for referral to colposcopy needs review. 261 
Furthermore, this threshold may well be breached with an increasingly vaccinated population. We do not yet 262 
have data to support alternative strategies based on vaccination status.  This would require robust linked data 263 
on vaccination status to implement safely  264 
 265 
In Scotland, the peak prevalence of CIN3 is found in 25-29 year old age band19 which accounts for almost a 266 
third of all cases per annum. The proportion of cases of CIN3 diagnosed in 20-24 year age band represents the 267 
2nd highest proportion at 21-24%. As the prevalence of CIN3 continues to fall over the next 5 years in both age 268 
groups, we need to ensure that any rationalisation of colposcopy services considers the need to maintain the 269 
necessary expertise to diagnose and treat women as part of cervical cancer prevention.  Whilst there are a 270 
number of new technologies which aim to be an adjuvant to traditional colposcopy20.21, their performance also 271 
relies on the prevalence of CIN in the referral population.  272 
 273 
It is inevitable that the anticipated potential of vaccination to reduce cervical cancer in the future will reduce 274 
secondary prevention activity; service planning needs to address this foreseeable change.  Should colposcopy 275 
training and staffing be allowed to undergo attrition, or should the existing clinical capacity be used for other 276 
patient groups who would benefit from the same clinical expertise? Whilst colposcopy skills are transferrable 277 
to other lower genital tract sites, this will require upskilling for staff who currently only deal with cervical 278 
disease.   279 
 280 
Conclusion 281 
A reduction in colposcopy workload is likely to be related to the HPV immunisation.  Review of service 282 
provision (including referral criteria) which takes into account the increasing number of vaccinated women who 283 
will enter screening is required to ensure the continued delivery of an effective colposcopy service. 284 
 285 
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 364 
 Group 1 N (column %) 
N=198* 
Group 2 N (column %) 
N=163 
Overall 
N=361 
Vaccinated 
67 (41.1) 
Unvaccinated 
96 (58.9 ) 
Site 
Site 1 95 (48.0) 53 (79.1) 93 (96.9) 241 (66.8) 
Site 2 103 (52.0) 14 (20.9) 3 (3.1) 120 (33.2) 
Age at colposcopy 
20 years 42 (21.2) 17 (25.4) 5 (5.2) 64 (17.7) 
21 years 33 (16.7) 31 (46.3) 5 (5.2) 69 (19.1) 
22 years 29 (14.6) 14 (20.9) 18 (18.8) 61 (16.9) 
23 years 39 (19.7) 3 (4.5) 31 (32.3) 73 (20.2) 
24 years 40 (20.2) 1 (1.5) 17 (17.7) 58 (16.1) 
25 years 15 (7.6) 1 (1.5) 20 (20.8) 36 (10.0) 
Mean Age (years) 22.2 (SD 1.6) 21.2(SD 1.0) 23.2 (SD 1.4) 22.3 (SD 1.6) 
Referral Cytology 
Borderline 46 (23.2) 19 (28.4) 27 (28.1) 92 (25.5) 
Mild dyskaryosis 86 (43.4) 34 (50.7) 28 (29.2) 148 (41.0) 
Moderate dyskaryosis 36 (18.2) 12 (17.9) 28 (29.2) 76 (21.1) 
Severe dyskaryosis 24 (12.1) 2 (3.0) 11 (11.5) 37 (10.2) 
Glandular neoplasia 1 (0.5) - 2 (2.1) 3 (0.8) 
Invasive cancer 1 (0.5) - - 1 (0.3) 
Missing 4 (2) - - 4 (1.1) 
Histology 
Biopsy not taken± 61 (30.8) 27 (40.3) 20 (20.8) 108 (29.9) 
Normal (No CIN) 19 (9.6) 9 (13.4) 10 (10.4) 38 (10.5) 
CIN1 53 (26.8) 18 (26.9) 24 (25.0) 95 (26.3) 
CIN2 35 (17.7) 9 (13.4) 23 (24.0) 67 (18.6) 
CIN3 24 (12.1) 3 (4.5) 14 (14.6) 41 (11.4) 
Invasive squamous 1a1 1 (0.5) - 1 (1.0) 2 (0.6) 
CGIN 2 (1.0) - 4 (4.2) 6 (1.7) 
Unsatisfactory 3 (1.5) 1 (1.5) - 4 (1.1) 
Table 1: Comparison of participant demographics between groups."Vaccinated" women refer to women who had 365 
received 2 or more doses of the HPV vaccination. *Group 1 includes 3 women who reported they had received the HPV 366 
vaccine.  ±All cases where biopsy was not taken were because colposcopic appearances were normal. 367 
368 
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Unvaccinated 
n/N (%) 
Vaccinated n/N 
(%) 
chi squared p-
value* (Pearson 
unless indicated) 
Colposcopic Features 
Acetowhite 231/291 (79.4) 54/70 (77.1) 0.623 
Mosaic 129/291 (44.3) 30/70 (42.9) 0.791 
Punctation 111/291 (38.1) 27/70 (38.6) 1.00 
Atypical Vessels 3/291 (1.0) 1/70 (1.4) 0.589 ? 
Iodine Negative** 101/202 (50.0) 33/59 (55.9) 0.442 
Colposcopic Opinion 
High Grade*** 99/290 (34.1) 13/66 (19.7) 0.027 
Histology**** 
CIN2+ 103/286 (36.0) 13/69 (18.8) 0.006 
CIN1+ 179/286 (62.6) 32/69 (46.3) 0.044 ? 
Table 2 compares the features seen at colposcopy between all participants regardless of disease status who were 371 
vaccinated against HPV 16 and 18, and women who were not. It also compares the colposcopic opinion and histology 372 
results between these groups. In patients where biopsies were not taken, they were considered to have no 373 
ĚŝƐĞĂƐĞ ? ?WĞĂƌƐŽŶ ?ƐƚĞƐƚƵƐĞĚƵŶůĞƐƐŽƚŚĞƌǁŝƐĞŝŶĚŝĐĂƚĞĚ ? ?&ŝƐŚĞƌ ?ƐĞǆĂĐƚƚĞƐƚƵƐĞĚ ? ? ?ŝŶ ?00 cases, iodine was not used. 374 
This was for a variety of reasons including patient allergy or colposcopist preference. ***High grade colposcopic opinion 375 
ǁĂƐĂƉƉĞĂƌĂŶĐĞƐƵŐŐĞƐƚŝǀĞŽĨ/E ?н ?  ? ? ? ?,ŝƐƚŽůŽŐǇƌĞƐƵůƚƐǁĞƌĞ ?ƵŶƐĂƚŝƐĨĂĐƚŽƌǇ ?ĨŽƌ ?ƵŶǀĂĐĐŝŶĂƚĞĚĂŶĚ 1 vaccinated 376 
therefore were excluded from histology analysis.  377 
378 
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 Unvaccinated 
(95% CI) 
N=294 
Vaccinated 
(95% CI) 
N=67 
z-test for 
difference 
 HPV 16+ 
(95% CI) 
N=142 
HPV 16 - 
(95% CI) 
N=219 
z-test for 
difference 
Sensitivity 
69.6 
(59.6-78.1) 
66.7  
(35.4-88.7) 
p=0.835 
 
65.8  
(53.9-76.0) 
76.3  
(59.4-88.0) 
p=0.251 
Specificity 
86.3  
(80.2-90.7) 
92.5  
(80.9-97.6) 
p=0.228 
 
75.0  
(62.3-84.6) 
92.4  
(87.1-95.7) 
p<0.001 
PPV 
74.0  
(63.8-82.1) 
66.7  
(35.4-88.7) 
p=0.591 
 
75.8  
(63.4-85.1) 
69.0  
(52.8-81.9) 
p=0.443 
NPV 
83.5  
(77.3-88.4) 
92.5  
(80.9-97.6) 
p=0.103 
 
64.9  
(52.8-75.4) 
94.6  
(89.7-97.3) 
p<0.001 
Table 3: Predictive values of colposcopy for detecting high grade disease where histology results were considered "gold 381 
standard" and the test was colposcopic opinion. This has been done to compare predictive values between vaccinated 382 
and unvaccinated participants and between participants who are HPV 16 positive and negative.  383 
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